Skip to Main content Skip to Navigation
Journal articles

The anti-IgE mAb Omalizumab induces adverse reactions by engaging Fcγ receptors

Abstract : Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of Omalizumab is associated with reported side effects, ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms through which Omalizumab induces adverse reactions are still unknown. Here, we demonstrated that immune complexes formed between Omalizumab and IgE can induce both skin inflammation and anaphylaxis through engagement of IgG receptors (FcγRs) in FcγR-humanized mice. We further developed an Fc-engineered mutant version of Omalizumab, and demonstrated that this mAb is equally potent as Omalizumab at blocking IgE-mediated allergic reactions, but does not induce FcγR-dependent adverse reactions. Overall, our data indicate that Omalizumab can induce skin inflammation and anaphylaxis by engaging FcγRs, and demonstrate that Fc-engineered versions of the mAb could be used to reduce such adverse reactions.
Document type :
Journal articles
Complete list of metadatas

Cited literature [4 references]  Display  Hide  Download

https://hal-pasteur.archives-ouvertes.fr/pasteur-02451133
Contributor : Pierre Bruhns <>
Submitted on : Thursday, January 23, 2020 - 11:10:44 AM
Last modification on : Saturday, October 17, 2020 - 3:14:03 AM
Long-term archiving on: : Friday, April 24, 2020 - 2:32:17 PM

File

Balbino_OMA_JCI_MS_102319_revi...
Files produced by the author(s)

Identifiers

Citation

Bianca Balbino, Pauline Herviou, Ophélie Godon, Julien Stackowicz, Odile Richard-Le Goff, et al.. The anti-IgE mAb Omalizumab induces adverse reactions by engaging Fcγ receptors. Journal of Clinical Investigation, American Society for Clinical Investigation, 2019, ⟨10.1172/JCI129697⟩. ⟨pasteur-02451133⟩

Share

Metrics